# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-30 of 568 results.
CNS Prophylaxis in Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Jun 06, 2016
First Received: May 19, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Methotrexate
Locations: University Hospital Brno-Bohunice, Brno, Czech Republic
University Hospital Hradec Králové, Hradec Králové, Czech Republic
University Hospital Ostrava, Ostrava, Czech Republic
University Hospital Pilsen, Pilsen, Czech Republic
University Hospital Kralovske Vinohrady, Prague, Czech Republic
... and 2 other locations.
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 16, 2019
First Received: Jan 09, 2019
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Gut microbiota samples
Locations: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
Institute Of Hematology "Seràgnoli", Bologna, Italy
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Jul 19, 2019
First Received: Jul 19, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): CTA101
Locations: the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Apr 09, 2019
First Received: Oct 25, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Methotrexate, Cytarabine
Locations: Helena Lau, Providence, Rhode Island, United States
Mature B-Cell Lymphoma And Leukemia Study III
Status: Recruiting
Last Changed: Jul 18, 2019
First Received: Jan 12, 2010
Disease(s): Mature B-Cell Lymphoma
Intervention(s): COPAD, COP, COPD M3, CYM, COP, COPADM8, CYVE
Locations: Rady Children's Hospital San Diego, San Diego, California, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Children's Cancer Hospital, Cairo, Egypt
National University Health System, Singapore, Singapore
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Status: Recruiting
Last Changed: Sep 14, 2017
First Received: Jul 05, 2017
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide
Locations: Beijing Cancer Hosptical, Beijing, China
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Jul 10, 2019
First Received: Jul 03, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Idelalisib
Locations: Aarhus University Hospital, Aarhus C, Denmark
Odense University Hospital, Odense, Denmark
Halmstad County Hospital, Halmstad, Sweden
Linkoping University Hospital, Linköping, Sweden
Skane University Hospital, Lund, Sweden
... and 2 other locations.
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Status: Not yet recruiting
Last Changed: Aug 29, 2018
First Received: Aug 29, 2018
Disease(s): Diffuse Large B-Cell Lymphoma, Unspecified Site
Intervention(s): G-CHOP, R-CHOP
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 18, 2019
First Received: Sep 24, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Radiation Therapy
Locations: Mayo Clinic, Rochester, Minnesota, United States
Duke University Medical Center, Durham, North Carolina, United States
Juntendo University, Tokyo, Japan
Yonsei University Health System, Seoul, Korea, Republic of
National Cancer Center of Singapore, Singapore, Singapore
... and 1 other locations.
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
Status: Recruiting
Last Changed: Aug 07, 2018
First Received: Jan 30, 2018
Disease(s): Lymphoma, B-Cell
Intervention(s): ET190L1 ARTEMIS™ T cells
Locations: Peking University Cancer Hospital, Beijing, China